{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:57:56Z","timestamp":1774612676531,"version":"3.50.1"},"reference-count":4,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.seizure.2020.06.008","type":"journal-article","created":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T02:18:27Z","timestamp":1591409907000},"page":"157-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3247-4246","authenticated-orcid":false,"given":"Sara","family":"G\u00f3mez-Enjuto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virgilio","family":"Hernando-Requejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Lape\u00f1a-Motilva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Ogando-Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Fouz-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Domingo-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Rodr\u00edguez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Alberto","family":"Cemill\u00e1n-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10234","key":"10.1016\/j.seizure.2020.06.008_bib0005","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2020.06.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmii.2020.03.005","article-title":"TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib","author":"Wu","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"issue":"2","key":"10.1016\/j.seizure.2020.06.008_bib0015","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JCO.2013.49.6166","article-title":"Management of posterior reversible encephalopathy syndrome induced by Carfilzomib in a patient with multiple myeloma","volume":"34","author":"Cai","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.seizure.2020.06.008_bib0020","doi-asserted-by":"crossref","first-page":"680","DOI":"10.4103\/ijccm.IJCCM_250_18","article-title":"Verapamil as an adjuvant treatment for drug-resistant epilepsy","volume":"22","author":"Lakshmikanthcharan","year":"2018","journal-title":"Indian J Crit Care Med"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120301709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120301709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:56:45Z","timestamp":1761011805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131120301709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":4,"alternative-id":["S1059131120301709"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2020.06.008","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2020.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}